Andritz AG (OTCMKTS:ADRZY – Get Free Report) was the recipient of a significant drop in short interest in March. As of March 31st, there was short interest totalling 1,200 shares, a drop of 42.9% from the March 15th total of 2,100 shares. Based on an average daily trading volume, of 30,100 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company’s stock are sold short.
Andritz Price Performance
ADRZY opened at $11.99 on Thursday. Andritz has a 1 year low of $9.35 and a 1 year high of $14.32. The firm’s fifty day moving average price is $12.06 and its two-hundred day moving average price is $11.67. The company has a market capitalization of $6.23 billion, a price-to-earnings ratio of 11.00 and a beta of 0.88. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.16 and a quick ratio of 0.89.
Andritz (OTCMKTS:ADRZY – Get Free Report) last announced its earnings results on Thursday, March 6th. The company reported $0.33 earnings per share (EPS) for the quarter. The firm had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.34 billion. Andritz had a return on equity of 23.10% and a net margin of 5.90%. As a group, analysts anticipate that Andritz will post 1.1 earnings per share for the current fiscal year.
Andritz Increases Dividend
Wall Street Analysts Forecast Growth
Separately, BNP Paribas raised Andritz from a “hold” rating to an “outperform” rating in a report on Thursday, April 3rd.
Check Out Our Latest Stock Analysis on Andritz
Andritz Company Profile
Andritz AG provides plants, equipment, and services for pulp and paper industry, metalworking and steel industries, hydropower stations, and solid/liquid separation in the municipal and industrial sectors in Europe, North America, South America, China, Asia, and internationally. It operates through four segments: Pulp & Paper, Metals, Hydro, and Separation.
See Also
- Five stocks we like better than Andritz
- What is the S&P/TSX Index?
- Viking Therapeutics Stock Pops But Struggles to Hold Gains
- Buy P&G Now, Before It Sets A New All-Time High
- Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited
- 3 Healthcare Dividend Stocks to Buy
- Meta Stock Holds Upside Potential as Analysts Cut Price Targets
Receive News & Ratings for Andritz Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Andritz and related companies with MarketBeat.com's FREE daily email newsletter.